Abstract: Disclosed is a composition for treating or preventing amyloid-related diseases including 4-O-methylhonokiol as an active ingredient. More specifically, a pharmaceutical composition including 4-O-methylhonokiol, which is effective for treating or preventing amyloid-related diseases such as Alzheimer's disease, cognitive disorder, defective memory, amyloidosis, etc. is disclosed. The inventors of the present disclosure have found out for the first time that 4-O-methylhonokiol inhibits the production of ?-amyloid. It has been confirmed to be useful in treating or preventing amyloid-related diseases. Through animal tests including water maze test and passive avoidance test on mice, 4-O-methylhonokiol has been confirmed to be effective for amyloid-related diseases such as Alzheimer's disease, defective memory, cognitive disorder, and the like.

Abstract: Disclosed is an anti-aging composition for external use on skin, which includes low-molecular weight hyaluronic acids, high-molecular weight hyaluronic acids and polysaccharides extracted from root bark of Ulmus davidiana, as active ingredients. The composition including the low-molecular weight hyaluronic acids, high-molecular weight hyaluronic acids and polysaccharides extracted from root bark of Ulmus davidiana, in a predetermined ratio, shows significantly improved skin-moisturizing, skin elasticity-enhancing and inflammation-alleviating effects, as compared to a composition using one of the above ingredients alone. Therefore, the composition may be widely used as a pharmaceutical or cosmetic anti-aging composition.

Abstract: Provided are a pharmaceutical composition, a cosmetic composition and health foods for preventing and treating alopecia disorder, which include a norgalanthamine compound as an active ingredient. Since the norgalanthamine compound has an effect on growth and proliferation of dermal papilla cells that play an important role in hair growth, the norgalanthamine compound may be used for the pharmaceutical composition, the cosmetic composition and health foods, which are useful in preventing and treating alopecia disorder.

Abstract: Disclosed is a composition for treating or preventing amyloid-related diseases including 4-O-methylhonokiol as an active ingredient. More specifically, a pharmaceutical composition including 4-O-methylhonokiol, which is effective for treating or preventing amyloid-related diseases such as Alzheimer's disease, cognitive disorder, defective memory, amyloidosis, etc. is disclosed. The inventors of the present disclosure have found out for the first time that 4-O-methylhonokiol inhibits the production of ?-amyloid. It has been confirmed to be useful in treating or preventing amyloid-related diseases. Through animal tests including water maze test and passive avoidance test on mice, 4-O-methylhonokiol has been confirmed to be effective for amyloid-related diseases such as Alzheimer's disease, defective memory, cognitive disorder, and the like.

Abstract: Disclosed is an anti-aging composition for external use on skin, which includes low-molecular weight hyaluronic acids, high-molecular weight hyaluronic acids and polysaccharides extracted from root bark of Ulmus davidiana, as active ingredients. The composition including the low-molecular weight hyaluronic acids, high-molecular weight hyaluronic acids and polysaccharides extracted from root bark of Ulmus davidiana, in a predetermined ratio, shows significantly improved skin-moisturizing, skin elasticity-enhancing and inflammation-alleviating effects, as compared to a composition using one of the above alone. Therefore, the composition may be widely used as a pharmaceutical or cosmetic anti-aging composition.

Abstract: A thiazole compound represented by general formula (I), wherein R is hydrogen atom, a hydroxy group, a straight or branched C.sub.1 -C.sub.6 lower alkyl group, a C.sub.1 -C.sub.4 lower alkoxy group, phenyl group, a phenyl group having one to three substituents selected from a group consisting of a C.sub.1 -C.sub.4 lower alkyl group, a C.sub.1 -C.sub.4 lower alkoxy group, fluorine, chlorine, bromine and an amino group, a C.sub.1 -C.sub.5 alkylphenyl group, a phenyl group having one to three substituents selected from a group consisting of a C.sub.1 -C.sub.4 lower alkyl group, a C.sub.1 -C.sub.4 lower alkoxy group, fluorine, chlorine, bromine and an amino group, a substituted or unsubstituted guanidino group, or an amino group having a general formula: NR.sub.3 R.sub.4 in which R.sub.3 and R.sub.4, identical to or different from each other, represent independently a hydrogen atom, a C.sub.1 -C.sub.6 lower alkyl group, a C.sub.3 -C.sub.

Abstract: Novel 4-amino-3-acylnaphthyridine derivatives represented by formula (I), wherein R.sub.1 is hydrogen, C.sub.1 -C.sub.6 lower alkyl group, C.sub.1 -C.sub.6 lower alkoxy group, C.sub.1 -C.sub.6 lower alkoxyalkyl group, C.sub.3 -C.sub.6 cycloalkyl group, C.sub.3 -C.sub.6 cycloalkyl C.sub.1 -C.sub.6 alkyl group, a or phenyl group which maybe substituted with C.sub.1 -C.sub.6 alkyl group; R.sub.2 is hydrogen, C.sub.1 -C.sub.6 lower alkyl group, C.sub.1 -C.sub.6 alkoxy group, C.sub.1 -C.sub.6 alkylthio group, or a group of the formula: NR.sub.6 R.sub.7 wherein R.sub.6 and R.sub.7, identical to or different from each other, are independently hydrogen or C.sub.1 -C.sub.6 lower alkyl group, or R.sub.6 and R.sub.7 may form together 5-membered or 6-membered cycloalkyl group; R.sub.3 is hydrogen, C.sub.1 -C.sub.6 lower alkyl group, C.sub.1 -C.sub.6 alkoxy group, C.sub.1 -C.sub.6 alkylthio group, an amino group substituted with one or two C.sub.1 -C.sub.6 alkyl groups, halogen, cyano group, C.sub.1 -C.sub.